Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicover ABLTS:0RPS -0.82%87 3-Year EBITDA Growth Rate is 19.50% as of Jun. 2026, which is 29% below its 10-year median of 27.30. GuruFocus rates LTS:0RPS with a GF Score™ of 87/100 and a GF Value™ of kr232.94 (Fairly Valued). The stock has 6 warning signs investors should review. Among 525 Healthcare Providers & Services companies, Medicover AB ranks better than 65.71% on this metric.
During the past 12 months, Medicover AB's average EBITDA Per Share Growth Rate was 12.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 25.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medicover AB was 42.70% per year. The lowest was 3.70% per year. And the median was 27.30% per year.
Medicover AB (LTS:0RPS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medicover AB 3-Year EBITDA Growth Rate Related Terms
LTS:0RPS vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Medicover AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicover AB 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medicover AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medicover AB's 3-Year EBITDA Growth Rate falls into.
Medicover AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.50% mean?
Medicover AB (LTS:0RPS) has a 3-Year EBITDA Growth Rate of 19.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medicover AB and its competitors. This is 29% below median its historical median of 27.30. Over the past decade, Medicover AB's 3-Year EBITDA Growth Rate has ranged from 3.70 to 42.70. According to the industry distribution chart, Medicover AB ranks #180 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 34.3%.
Is Medicover AB's 3-Year EBITDA Growth Rate too high?
Medicover AB's current 3-Year EBITDA Growth Rate of 19.50% is 29% below median its 10-year median of 27.30. Over the past 10 years, this metric has ranged from a low of 3.70 to a high of 42.70. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Medicover AB's value of 19.50% is 97% above this industry median. Based on the distribution chart, Medicover AB ranks #180 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Medicover AB has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medicover AB's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medicover AB ranks #180 out of 525 companies for 3-Year EBITDA Growth Rate. This puts Medicover AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. Medicover AB's value of 19.50% is 97% above this benchmark. Historically, Medicover AB's own 3-Year EBITDA Growth Rate has ranged from 3.70 to 42.70 over the past decade. While the company's 10-year median is 27.30 vs. the industry median of 9.90, Medicover AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicover AB's current 3-Year EBITDA Growth Rate of 19.50% is 97% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medicover AB and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicover AB's current 3-Year EBITDA Growth Rate is 19.50%, which is 29% below median its own 10-year median of 27.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicover AB stock overvalued right now?
Based on GuruFocus' analysis, Medicover AB (LTS:0RPS) is currently considered Fairly Valued. The stock's GF Value™ is kr232.94, compared to a current price of kr242.00 — trading 3.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.50%, which is 29% below median its 10-year median of 27.30 and 97% above the Healthcare Providers & Services industry median of 9.90. Medicover AB's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medicover AB (LTS:0RPS), the current 3-Year EBITDA Growth Rate is 19.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicover AB (LTS:0RPS) Overvalued in 2026?
Based on GuruFocus' analysis, Medicover AB stock appears to be overvalued.
The current stock price of kr242.00 is trading 3.9% above its estimated GF Value™ of kr232.94.
GuruFocus considers Medicover AB to be Fairly Valued.
Key valuation signals for LTS:0RPS:
3-Year EBITDA Growth Rate: 19.50% (29% below median its 10-year median of 27.30)
GF Value™: kr232.94 vs. price of kr242.00 (3.9% above fair value)
Industry Position: 97% above the Healthcare Providers & Services median (#180 of 525)
No single metric tells the full story. See the LTS:0RPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicover AB is an international healthcare and diagnostic services provider. It offers a broad spectrum of healthcare services via an extensive network of ambulatory clinics, hospitals, specialty-care facilities, and laboratories. Medicover offers its services through two reportable segments: Healthcare Services, which generates the maximum revenue, and Diagnostic Services. Diagnostic Services offer a broad range of laboratory testing in all clinical pathology areas, and Healthcare Services offer medical care and related services by operating on an Integrated Healthcare and Fee-For-Service model across different countries. Geographically, the company derives maximum revenue from Germany, and the rest from Poland, India, Ukraine, Romania, and other countries.
87GF Score
Get the complete analysis for LTS:0RPS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RPS has been successfully added to your 
